Pivotal studies of pharmacotherapies approved by the US FDA for cancer treatment: a meta-analysis
OncologiaSobre o estudo
- Desenho
- Metanálise
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- The oncologist
- Publicado em
- 10 abr 2026
- Citações
- 0
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Pivotal studies of pharmacotherapies approved by the US FDA for cancer treatment: a meta-analysis
Ronald Chow, James H B Im, Camilla Zimmermann, Georgia C Richards, Carl Heneghan
Descritores MeSH
- Antineoplastic Agents
- Neoplasms
- Drug Approval
- Humans
- United States
- United States Food and Drug Administration
Veja também
Estudos relacionados
- Longitudinal changes in the relative toxicity of FDA-approved oncology therapeutics: evidence from paired initial and updated RCT reports
- Evolution of clinical benefit in cancer trials: comparing pivotal approval data with updated efficacy
- Review of All Solid Tumor Drug Approvals From 2019 to 2024 by US Food and Drug Administration, European Medicines Agency, and Brazilian Health Regulatory Agency
- Postrecurrence Treatment in Neoadjuvant or Adjuvant FDA Registration Trials: A Systematic Review